AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...
News Medical on MSN18h
Using bioengineered materials to treat chemotherapy-induced oral lesionsA new research paper was published in , Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters' model: A regenerative approach using ...
Scarlett, a retired thoroughbred racehorse and descendant of Secretariat, has become like family for Jenna and her parents, Kim and Matt.
To our knowledge, this is the first-in-animal preliminary study, which used a biocompatible electrospun membrane with the addition of autologous ...
The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...
This is just one of many congenital diseases that can affect pets. Congenital diseases are disorders or abnormalities that ...
The Company's net loss was $19.0 million for the year ended December 31, 2024, compared to $22.3 million for the year ended ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback